论文部分内容阅读
目的观察阿托伐他汀钙联合依折麦布治疗老年冠心病的效果。方法采用随机数字表法将104例老年冠心病患者分成两组,对照组(52例)给予阿托伐他汀钙进行治疗,实验组(52例)则进行阿托伐他汀钙联合依折麦布治疗,2周为1个疗程,治疗3个疗程。对比治疗前后两组血脂以及炎性反应情况、治疗效果、不良反应发生情况。计量资料比较采用t检验,计数资料比较采取χ~2校验,P<0.05为差异有统计学意义。结果治疗后,实验组TC(4.23±1.20)mmol/L、LDL-C(2.13±0.25)mmol/L、hs-CRP(2.13±0.25)mmol/L低于对照组[(5.05±1.45)、(3.03±0.22)、(5.03±1.10)mmol/L],比较差异有统计学意义(均P<0.05);实验组总有效率96.15%高于对照组总有效率76.92%,比较差异有统计学意义(P<0.05);实验组不良反应发生率7.69%低于对照组26.92%,比较差异有统计学意义(P<0.05)。结论阿托伐他汀钙联合依折麦布治疗老年冠心病能有效降低患者血脂及hs-CRP水平,临床疗效显著,不良反应发生率低。
Objective To observe the effect of atorvastatin combined with ezetimibe on elderly patients with coronary heart disease. Methods 104 cases of elderly patients with coronary heart disease were divided into two groups by random number table method. The control group (52 cases) was treated with atorvastatin calcium. In the experimental group (52 cases), atorvastatin calcium combined with ezetimibe Treatment, 2 weeks for a course of treatment, treatment 3 courses. Compare the two groups before and after treatment of blood lipids and inflammatory response, treatment, adverse reactions occurred. Measurement data were compared using t test, count data to compare χ ~ 2 test, P <0.05 for the difference was statistically significant. Results Compared with the control group (5.05 ± 1.45), TC (4.23 ± 1.20) mmol / L, LDL-C (2.13 ± 0.25) mmol / (3.03 ± 0.22) and (5.03 ± 1.10) mmol / L, respectively, with statistical significance (all P <0.05). The total effective rate in experimental group was 96.15%, which was 76.92% higher than that in control group (P <0.05). The incidence of adverse reactions in the experimental group was 7.69% lower than that in the control group (26.92%), with significant difference (P <0.05). Conclusion Combination of atorvastatin and ezetimibe in the treatment of elderly patients with coronary heart disease can effectively reduce the level of serum lipids and hs-CRP. The clinical efficacy is significant and the incidence of adverse reactions is low.